# TALENTACE (NCT04712643)

> A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04712643
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Hepatocellular Carcinoma
- Interventions: Atezolizumab; Becavizumab; Transarterial chemoembolization (TACE)
- Enrollment: 342
- Primary outcome: TACE Progression-Free Survival (TACE PFS) as Determined by Investigator
- Primary outcome: Overall Survival (OS)

## Indexed commentary on TALENTACE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 6
- Podcasts: 5
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=talentace-nct04712643

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04712643", "email": "<work email>"}; the inbox owner confirms by the emailed link.